How long do you stay on Wegovy — and what happens when you stop?

The myth that Wegovy is a short-term fix you stop once you hit your target

The biggest misconception our prescribers hear most weeks is that Wegovy works like a diet, you use it, reach your goal weight, then stop and carry on as before. That is not how the medicine works, and the trial data are unambiguous about it. Obesity is a chronic condition influenced by hormones, genetics and physiology; semaglutide acts on GLP-1 receptors to reduce appetite and slow gastric emptying. When you stop, those receptors no longer receive that signal, hunger patterns return, and the body tends to defend the weight it held before treatment.

The STEP 1 trial, published in the New England Journal of Medicine, followed up participants who stopped semaglutide 2.4mg after 68 weeks and found that most regained the majority of their lost weight within a year of discontinuation. That is not a failure of the medicine; it is a feature of the underlying condition. Understanding this reframes the question entirely, for many people, the relevant question is less "how long do you stay on it?" and more "what is the plan for sustained weight management?" If you are weighing up the upper limits of treatment, our page on how long you can stay on Wegovy sets out what the evidence and guidance say about extended use. You can also read more about the distinction on our page covering how long you can stay on Wegovy for weight loss.

None of this means everyone must take Wegovy indefinitely. Some people reach a health goal, build lasting habits, and work with their prescriber to taper off with a structured plan. The point is simply that stopping abruptly because a target number on the scales has been reached (without clinical guidance) is rarely the right approach.

What the NICE guidance and the licensed indication actually say

There are two different frameworks here, and confusing them is common. NICE technology appraisal TA875 recommends semaglutide (Wegovy) on the NHS only within a specialist weight management service (multidisciplinary care including dietary, activity and behavioural support) and for a maximum of two years. If less than five percent of body weight has been lost after six months at the maintenance dose, continuing treatment is not recommended under that guidance. These restrictions reflect the commissioning context of NHS specialist services, not a fixed biological limit on how long the medicine can safely be used.

The licensed indication for Wegovy, as granted by the MHRA, does not impose a two-year ceiling. It authorises use in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition, as an adjunct to a reduced-calorie diet and increased physical activity. Private prescribing operates within the licence rather than NICE's NHS commissioning criteria. That means your prescriber can continue treatment beyond two years provided it remains clinically appropriate, results are adequate, the medicine is tolerated, and your overall health picture supports continuation. A prescriber reviews this before every repeat. For a fuller breakdown of the NHS versus private distinction, our page on how long you have to stay on Wegovy covers what is a clinical requirement versus what is a commissioning rule, and this page on how long you need to stay on Wegovy covers the practical implications in detail.

The six-month review principle is worth keeping, regardless of route. It is a sensible checkpoint: is the medicine working well enough to justify continuing? Are side effects manageable? Have lifestyle changes been embedded alongside it? A good prescriber asks all of these.

How duration is decided in practice, and what affects it

There is no single answer to how long a person stays on Wegovy, because the decision turns on several variables that differ between individuals. The size of the clinical benefit matters: someone who has lost 15 percent of their body weight and seen their blood pressure normalise has a different risk-benefit picture from someone whose weight loss has plateaued at two percent after six months. The presence of weight-related conditions (cardiovascular disease, type 2 diabetes, sleep apnoea) can justify continued treatment even when weight loss slows, because those conditions themselves carry ongoing risk.

Tolerability is another factor. Some people experience gastrointestinal side effects including nausea, changes in bowel habit and reflux, particularly during dose escalation. For most, these settle as the body adjusts, but a small number find the side-effect burden outweighs the benefit at higher doses, and a prescriber will discuss whether staying at a lower maintenance dose, pausing, or stopping is the right call. You can find a full discussion of the side-effect profile on the Wegovy overview page.

Lifestyle integration matters too. Weight medicines work best alongside real changes in eating patterns and activity. People who use the treatment window to build sustainable habits tend to maintain more weight loss after stopping than those who rely on the medicine alone. That is not a moral judgement, it is just what the evidence shows. If you are thinking about where semaglutide sits within a broader weight management plan, our weight loss treatment overview lays out the options clearly.

For those wondering about duration specifically in the context of semaglutide more broadly, how long you stay on semaglutide for weight loss addresses that from the molecule's angle, which is useful if you are also considering how the injection and tablet forms compare.

Planning ahead: what a structured stop looks like, and when continuing makes sense

If you and your prescriber agree that stopping is the right decision, a gradual, planned approach is generally preferable to stopping abruptly. This gives your body time to adjust and allows your prescriber to monitor whether hunger patterns, blood pressure or blood glucose shift in ways that need attention. There is no standard taper schedule in the SmPC, the timing is a clinical decision based on your individual situation.

Continuing treatment long-term is not unusual, and it does not mean the medicine has "stopped working" or that you are dependent on it in any problematic sense. Ongoing use of a medicine to manage a chronic health condition is entirely normal clinical practice. Many people stay on Wegovy for several years under regular clinical review, with treatment reviewed and re-authorised before each supply. At nume, a prescriber (not an automated system) reviews every repeat request before anything is dispensed. If you want to understand how that process works in practice, our about page explains the clinical structure behind the service, and our clinical team page introduces the prescribers involved.

Whether you are exploring treatment for the first time or reassessing a plan already underway, the conversation starts with a consultation. It is the one place where duration, dose, goals and your individual health history can be considered together. If you have questions that are not answered here, our FAQs cover a wide range of common queries, or you can reach us directly through the contact page.